Cytophage Technologies Statistics
Total Valuation
TSXV:CYTO has a market cap or net worth of CAD 11.41 million. The enterprise value is 12.17 million.
Market Cap | 11.41M |
Enterprise Value | 12.17M |
Important Dates
The next estimated earnings date is Friday, August 29, 2025.
Earnings Date | Aug 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TSXV:CYTO has 61.69 million shares outstanding. The number of shares has increased by 21.37% in one year.
Current Share Class | 61.69M |
Shares Outstanding | 61.69M |
Shares Change (YoY) | +21.37% |
Shares Change (QoQ) | -0.01% |
Owned by Insiders (%) | 12.01% |
Owned by Institutions (%) | 1.81% |
Float | 53.93M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 6.44 |
P/TBV Ratio | 6.44 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.57 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -2.63 |
Financial Position
The company has a current ratio of 1.23, with a Debt / Equity ratio of 0.84.
Current Ratio | 1.23 |
Quick Ratio | 1.11 |
Debt / Equity | 0.84 |
Debt / EBITDA | n/a |
Debt / FCF | -0.32 |
Interest Coverage | -47.30 |
Financial Efficiency
Return on equity (ROE) is -114.52% and return on invested capital (ROIC) is -51.39%.
Return on Equity (ROE) | -114.52% |
Return on Assets (ROA) | -47.09% |
Return on Invested Capital (ROIC) | -51.39% |
Return on Capital Employed (ROCE) | -155.49% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.32% in the last 52 weeks. The beta is 0.09, so TSXV:CYTO's price volatility has been lower than the market average.
Beta (5Y) | 0.09 |
52-Week Price Change | -49.32% |
50-Day Moving Average | 0.21 |
200-Day Moving Average | 0.24 |
Relative Strength Index (RSI) | 45.28 |
Average Volume (20 Days) | 37,513 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -4.72M |
Pretax Income | -4.74M |
Net Income | -4.74M |
EBITDA | -4.32M |
EBIT | -4.72M |
Earnings Per Share (EPS) | -0.09 |
Balance Sheet
The company has 728,685 in cash and 1.49 million in debt, giving a net cash position of -758,200 or -0.01 per share.
Cash & Cash Equivalents | 728,685 |
Total Debt | 1.49M |
Net Cash | -758,200 |
Net Cash Per Share | -0.01 |
Equity (Book Value) | 1.77M |
Book Value Per Share | 0.03 |
Working Capital | 172,648 |
Cash Flow
In the last 12 months, operating cash flow was -3.39 million and capital expenditures -1.25 million, giving a free cash flow of -4.64 million.
Operating Cash Flow | -3.39M |
Capital Expenditures | -1.25M |
Free Cash Flow | -4.64M |
FCF Per Share | -0.08 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TSXV:CYTO does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -21.37% |
Shareholder Yield | n/a |
Earnings Yield | -41.53% |
FCF Yield | -40.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on February 9, 2024. It was a reverse split with a ratio of 0.2412662.
Last Split Date | Feb 9, 2024 |
Split Type | Reverse |
Split Ratio | 0.2412662 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |